Brief: Compass Pathways Announces Completion Of Recruitment For The Phase 3 COMP005 Trial Of COMP360 Psilocybin For Treatment-Resistant Depression
26/03/2025 11:54
March 26 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS ANNOUNCES COMPLETION OF RECRUITMENT FOR THE PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC: ON TRACK FOR TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS IN LATE Q2 COMPASS PATHWAYS PLC - COMP006 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026 Source text: ID:nBwcfJCBTa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications